Login
Enveric Biosciences, Inc. logo

Enveric Biosciences, Inc.

enveric.com

What Do They Do?

Develops small-molecule drug candidates for psychiatric and neurological disorders and plans to partner with pharmaceutical and biotechnology companies on their development and commercialization.

Who Are Their Customers?

Works with pharmaceutical and biotechnology companies through licensing and development partnerships: it has licensed drug portfolios to third parties and plans to partner on developing and commercializing psychedelic-inspired medicines.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −36% (Loss)
vs −$1.9M in Q3 FY2025

Focus on neuropsychiatric drug candidates The earlier report described developing cancer-related palliative and supportive-care products alongside small-molecule treatments for anxiety, depression and addiction. The latest report centers on non-hallucinogenic neuropsychiatric drug candidates, with its lead candidate as the primary focus.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support